Clene Inc. (CLNN)

Market Cap	43.65M
Revenue (ttm)	654,000
Net Income (ttm)	-49.50M
Shares Out	128.43M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,812
Open	0.347
Previous Close	0.347
Day's Range	0.330 - 0.354
52-Week Range	0.250 - 1.090
Beta	0.49
Analysts	Strong Buy
Price Target	7.20 (+2,018.27%)
Earnings Date	May 10, 2024

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: CLNN

Financial Performance

In 2023, Clene's revenue was $654,000, an increase of 38.27% compared to the previous year's $473,000. Losses were -$49.50 million, 65.5% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price forecast is $7.2, which is an increase of 2,018.27% from the latest price.

Price Target

$7.2

(2,018.27% upside)

Analyst Consensus: Strong Buy